Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 16

1.

Bardoxolone methyl and kidney function in CKD with type 2 diabetes.

Pergola PE, Raskin P, Toto RD, Meyer CJ, Huff JW, Grossman EB, Krauth M, Ruiz S, Audhya P, Christ-Schmidt H, Wittes J, Warnock DG; BEAM Study Investigators.

N Engl J Med. 2011 Jul 28;365(4):327-36. doi: 10.1056/NEJMoa1105351. Epub 2011 Jun 24.

2.

Prospective safety study of bardoxolone methyl in patients with type 2 diabetes mellitus, end-stage renal disease and peritoneal dialysis.

Warnock DG, Hebbar S, Bargman J, Burkart J, Davies S, Finkelstein FO, Mehrotra R, Ronco C, Teitelbaum I, Urakpo K, Chertow GM.

Contrib Nephrol. 2012;178:157-63. doi: 10.1159/000337837. Epub 2012 May 25. Review.

PMID:
22652731
3.

Cardiac and renal function in patients with type 2 diabetes who have chronic kidney disease: potential effects of bardoxolone methyl.

McCullough PA, Ali S.

Drug Des Devel Ther. 2012;6:141-9. doi: 10.2147/DDDT.S26714. Epub 2012 Jun 14. Review.

4.

Targeting inflammation: new therapeutic approaches in chronic kidney disease (CKD).

Impellizzeri D, Esposito E, Attley J, Cuzzocrea S.

Pharmacol Res. 2014 Mar;81:91-102. doi: 10.1016/j.phrs.2014.02.007. Epub 2014 Mar 3. Review.

PMID:
24602801
5.

Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD.

Keam SJ, Keating GM.

Treat Respir Med. 2004;3(4):247-68. Review.

PMID:
15350163
6.

Mitoxantrone: a review of its use in multiple sclerosis.

Scott LJ, Figgitt DP.

CNS Drugs. 2004;18(6):379-96. Review.

PMID:
15089110
7.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID:
15099124
8.

Targeting the transcription factor Nrf2 to ameliorate oxidative stress and inflammation in chronic kidney disease.

Ruiz S, Pergola PE, Zager RA, Vaziri ND.

Kidney Int. 2013 Jun;83(6):1029-41. doi: 10.1038/ki.2012.439. Epub 2013 Jan 16. Review.

9.

A preliminary evaluation of bardoxolone methyl for the treatment of diabetic nephropathy.

Thomas M.

Expert Opin Drug Metab Toxicol. 2012 Aug;8(8):1015-22. doi: 10.1517/17425255.2012.697152. Epub 2012 Jun 30. Review.

PMID:
22747345
10.

The Nrf2 pathway in the progression of renal disease.

Zoja C, Benigni A, Remuzzi G.

Nephrol Dial Transplant. 2014 Feb;29 Suppl 1:i19-i24. doi: 10.1093/ndt/gft224. Epub 2013 Jun 11. Review.

11.

Short- and long-term effects of alkali therapy in chronic kidney disease: a systematic review.

Susantitaphong P, Sewaralthahab K, Balk EM, Jaber BL, Madias NE.

Am J Nephrol. 2012;35(6):540-7. doi: 10.1159/000339329. Epub 2012 May 29. Review.

12.

Managing chronic inflammation in the aging diabetic patient with CKD by diet or sevelamer carbonate: a modern paradigm shift.

Vlassara H, Cai W, Chen X, Serrano EJ, Shobha MS, Uribarri J, Woodward M, Striker GE.

J Gerontol A Biol Sci Med Sci. 2012 Dec;67(12):1410-6. doi: 10.1093/gerona/gls195. Epub 2012 Oct 29. Review.

13.

Does correction of metabolic acidosis slow chronic kidney disease progression?

Goraya N, Wesson DE.

Curr Opin Nephrol Hypertens. 2013 Mar;22(2):193-7. doi: 10.1097/MNH.0b013e32835dcbbe. Review.

PMID:
23380803
14.

Acid-base status and progression of chronic kidney disease.

Goraya N, Wesson DE.

Curr Opin Nephrol Hypertens. 2012 Sep;21(5):552-6. doi: 10.1097/MNH.0b013e328356233b. Review.

PMID:
22874469
15.

Antioxidants for chronic kidney disease.

Jun M.

Nephrology (Carlton). 2013 Aug;18(8):576-8. doi: 10.1111/nep.12103. Review. No abstract available.

PMID:
23865542
16.

Horizon 2020 in Diabetic Kidney Disease: The Clinical Trial Pipeline for Add-On Therapies on Top of Renin Angiotensin System Blockade.

Perez-Gomez MV, Sanchez-Niño MD, Sanz AB, Martín-Cleary C, Ruiz-Ortega M, Egido J, Navarro-González JF, Ortiz A, Fernandez-Fernandez B.

J Clin Med. 2015 Jun 18;4(6):1325-47. doi: 10.3390/jcm4061325. Review.

Items per page

Supplemental Content

Write to the Help Desk